Related Experiment Video
Updated: Feb 3, 2026

The Measurement and Treatment of Suppression in Amblyopia
Published on: December 14, 2012
Making way for suppressing the FGF19/FGFR4 axis in cancer
Nestor Prieto-Dominguez1,2, Austin Y Shull3, Yong Teng1,4
1Department of Oral Biology, Dental College of Georgia, Augusta University, Augusta, GA, USA.
Abstract:
FGF19 is a noncanonical FGF ligand that can control a broad spectrum of physiological responses, which include bile acid homeostasis, liver metabolism and glucose uptake. Many of these responses are mediated by FGF19 binding to its FGFR4/β-klotho receptor complex and controlling activation of an array of intracellular signaling events. Overactivation of the FGF19/FGFR4 axis has been implicated in tumorigenic formation, progression and metastasis, and inhibitors of this axis have recently been developed for single agent use or in combination with other anticancer drugs. Considering the critical role of this receptor complex in cancer, this review focuses on recent developments and applications of FGF19/FGFR4-targeted therapeutics.
Insights
Fibroblast Growth Factor 19 (FGF19) regulates key physiological processes. Inhibiting the FGF19/FGFR4 pathway shows promise for novel cancer therapies.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Fibroblast Growth Factor 19 (FGF19) is a key regulator of bile acid homeostasis, liver metabolism, and glucose uptake.
- The FGF19/FGFR4/β-klotho receptor complex mediates these physiological responses through intracellular signaling.
- Overactivation of the FGF19/FGFR4 axis is linked to cancer development, progression, and metastasis.
Purpose of the Study:
- To review recent advancements in FGF19/FGFR4-targeted therapeutics.
- To explore the application of these targeted therapies in cancer treatment.
Main Methods:
- Literature review of recent studies on FGF19/FGFR4 axis.
- Analysis of therapeutic strategies targeting the FGF19/FGFR4 pathway.
- Examination of preclinical and clinical data for FGF19/FGFR4 inhibitors.
Main Results:
- FGF19/FGFR4 axis inhibitors are emerging as potential anticancer agents.
- These inhibitors are being developed for monotherapy and combination treatments.
- Targeting the FGF19/FGFR4 complex is a promising strategy in oncology.
Conclusions:
- The FGF19/FGFR4 axis plays a critical role in cancer.
- Targeted therapeutics offer a new avenue for cancer treatment.
- Further research into FGF19/FGFR4 inhibitors is warranted for effective cancer therapy.
More Related Videos
14:01Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
Published on: July 22, 2011
13:56Robot Assisted Distal Pancreatectomy with Celiac Axis Resection DP-CAR for Pancreatic Cancer: Surgical Planning and Technique
Published on: August 14, 2021
Related Concept Videos
Hypothalamic-Pituitary Axis
Perpendicular-Axis Theorem
Consider a circular disc of mass M and radius R lying along an x-y plane. The origin lies at the center of the disc, and the z-axis is perpendicular to the disc's plane. All three axes coincide at the disc's center. The moment of inertia of this...
Parallel-axis Theorem
Load along a Single Axis
Consider a beam of length L subjected to a varying load, which is a combination of parabolic and trapezoidal load distribution along the x-axis. In this case, it is essential to determine the resultant loads, their locations, and...
Parallel-Axis Theorem for an Area
For a flywheel approximated as a solid disc, consider an infinitesimal differential element with an arbitrary distance...
Moment of a Force About an Axis: Scalar
To better understand the concept of moment of force, consider the example of a cyclist riding a bicycle. When the cyclist applies force on...